Neurocrine Biosciences (NBIX) Preferred Stock Liabilities (2024)
Neurocrine Biosciences (NBIX) posted quarterly Preferred Stock Liabilities of $136.2 million for Q1 2024.
Neurocrine Biosciences (NBIX) Preferred Stock Liabilities (2024) Analysis & Trends
Neurocrine Biosciences has reported Preferred Stock Liabilities for 1 years, with the latest figure at $136.2 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 136.20 Mn |